IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Named Inventor: Stenkamp, Dirk, et al) Art Unit:

1626

Application No.:

10/699,089

Examiner:

Powers, Fiona

Filing Date:

MAY 3 1 2006

October 31, 2003

Confirmation No.:

1853

Title: Amide Compounds Having MCH-Antagonistic Activity and Medicaments Comprising

these Compounds

Attorney Docket No.:

1/1407

IDS STATEMENT(S)

	INFORMATION PREVIOUSLY CITED OF	R SUBMITTED				
	U.S. Application No.	("the parent application") is relied on by the				
	above-identified application for an earlier ef	fective filing date under 35 U.S.C. 120. The				
	patents, publications, pending U.S. application	ons, or other information listed in the instant				
	information disclosure statement were previously cited by the Office in the parent					
	application or submitted to the Office in the parent application in an information					
	disclosure statement that complied with 37	CFR 1.98(a)-(c). 37 CFR 1.98(d)				
X	The fee set forth in 37 CFR 1.17(p) has been	submitted herewith. 37 CFR 1.97(c-d)				
	Otherwise, the Applicant authorizes the char	ging of all fees set forth in §1.16 and to §1.17				
	to Deposit Account No 02-29955 for the ent	ire pendency of this application.				
	37 CFR 1.25(b)					
	INFORMATION FIRST CITED BY FOREI	GN PATENT OFFICE NOT MORE THAN				
	THREE (3) MONTH PRIOR					
	Each item of information contained in the in	stant information disclosure statement was				
	first cited in any communication from a fore	ign patent office in a counterpart foreign				
	application not more than three (3) months p	rior to the filing of the instant information				
	disclosure statement. 37 CFR 1.97(e)(1)					

NO INFORMATION KNOWN MORE THAN THREE (3) MONTHS PRIOR
No item of information contained in the instant information disclosure statement was
cited in a communication from a foreign patent office in a counterpart foreign application,
and, to the knowledge of the person signing this certification after making reasonable
inquiry, no item of information contained in the instant information disclosure statement
was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months
prior to the filing of the instant information disclosure statement. 37 CFR 1.97(e)(2)
NO INFORMATION RECEIVED FROM FOREIGN PATENT OFFICE MORE THAN
THIRTY (30) DAYS PRIOR
This submission contains only an information disclosure statement. Each item of
information contained in the instant information disclosure statement was first cited in

any communication from a foreign patent office in a counterpart application and this

than thirty (30) days prior to the filing of the instant information disclosure statement.

communication was not received by any individual designated in 37 C.F.R. §1.56(c) more

Respectfully submitted,

Γimothy X. Witkowski

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

37 CFR 1.704(d)

Tel: (203) 798-4310

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents

P. O. Box 1450 Alexandria, VA 22313-1450

on May 24, 2006

Timothy X. Witkowski

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

Complete if Known Application Number 10/699,089 Filing Date October 31, 2003 First Named Inventor Stenkamp, D.,et al Art Unit 1614 **Examiner Name** To be assigned

(Use as many sheets as necessary)

STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Attorney Docket Number 1/1407

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 3,994, 900	11/30/1976	Krapcho, John, et al	
		^{US-} 6,366,268 B1	04/02/2002	Forrest, S.R., et al	
		^{US-} 2002/0052383 A1	05/02/2002	Bakthavatchalam, R. et a	
		^{US-} 2005/0026915 A1	02/03/2005	DeVita, R.J., et al	
		^{US-} 2005/0009815 A1	01/13/2005	DeVita, R.J., et al	
		^{US-} 2004/0082780 A1	04/29/2004	Doherty, E.M., et al	
		^{US-} 2003/0192132 A1	10/16/2003	Chassot, L., et al	
		^{US-} 2004/0220191 AI	11/04/2004	Schwink, L., et al	
		^{US-} 2004/0142953 A1	07/22/2004	Delorme, D., et al	
		^{US-} 6,258,953 B2	07/10/2001	Howard, H.R., et al	
		US-			
-		US-			
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	_6		
fnitials*	No.'	Country Code ³ Number ⁴ 'Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	1 1 1		
		WO 2005/063239 A1	07/14/2005	Boehringer Ingelheim International GmbH				
		WO 2005/085221 A1	09/15/2005	Boehringer Ingelheim International GmbH				
		DE 1 088 955	09/15/1960	Farbenfabriken Bayer Ak				
	İ	DE 3016827	11/20/1980	Continental Pharam S.A., Brussel				
	İ	WO 2004/024702	03/25/2004	Boehringer Ingelheim Pharma Gmbh		П		

	_		
Examiner		Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	nder the Paperwork Reduction Act of 1995. Substitute for form 1449A/PTO	The services are regalited to re-	Complete if Known		
			Application Number	10/699,089	
	INFORMATION DISC	CLOSURE	Filing Date	October 31, 2003	
	STATEMENT BY AP	PLICANT	First Named Inventor	Stenkamp, D., et al	
			Art Unit	1614	
	(Use as many sheets as nec	essary)	Examiner Name	To be assigned	
She	et 2	of 10	Attorney Docket Number	1/1407	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-	——		
		US-	***************************************		
		US-	***************************************		
		US-		***************************************	
		US-			
		US-		AND AND PROPERTY OF THE PROPER	
		US-			
		US-		danden dreiffe försten die röff-samski-belande ist verbrik middenheiser braumenn mannennen segenga oppsysie.	
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	-r-6		
muais	NO.	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	WIVI-DD-1111	Applicant of Cited Document	or Relevant Figures Appear	L'_J		
		EP 1 593 667 A1	09/11/2005	Takeda Pharm. Co.				
		WO 2004/018467 A2	03/04/2004	BI Pharma GmbH				
	[WO 2004/041820 A1	05/21/2004	BI Pharma GmbH				
		WO 03/045313 A2	06/05/2003	Merck & Co. Inc.				
		EP 1 283 199 A1	02/12/2003	Takeda Chem. Ind.				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond Complete if Known Substitute for form 1449A/PTO **Application Number** 10/699,089 Filing Date INFORMATION DISCLOSURE October 31, 2003 First Named Inventor Stenkamp, D., et al STATEMENT BY APPLICANT Art Unit 1614 **Examiner Name** To be assigned (Use as many sheets as necessary) 10 Attorney Docket Number 1/1407

Examiner	Cite	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.'	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
····		US-			
		US-			
		US-		**************************************	
		ÜS-			
		US-			1.2-44-5-6-40-20-70-12-70-12-70-12-70-12-70-2-5-6-40-40-40-4-4-4-4-4-4-4-4-4-4-4-4-4-4-
		US-		**************************************	
		US-			· · · · · · · · · · · · · · · · · · ·
		US-		***************************************	
		US-			
		US-		rentient das aus sem le setemetre droit est de l'est de l'estre de le deman rentiember le destre finalise de l	
		US-			
		US-			
		US-			
		US-			**************************************
*****		US-			
*******		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Oocument Country Code ³ Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶		
		WO 01/55066 A2	08/02/2001	Syngenta Participat. In				
	1	WO 2004/039780 A1	05/13/2004	Boehringer Ingelheim		П		
		WO 02/04433 A2	01/17/2002	Neurogen Corporation				
		WO 03/013247 A1	02/20/2003	Syngenta Participat. Ir				
	1	WO 03/018579 A1	03/06/2003	Merck Frosst Canada				

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	nder the Paperwork Reduction Act of 1995 Substitute for form 1449A/PTO	, no per	sons are required to re-		ion unless it contains a valid OMB control nu mplete if Known	mber.
	Substitute for form 1445APTO			Application Number	10/699,089	
	INFORMATION DISC	CLO	SURE	Filing Date	October 31, 2003	
	STATEMENT BY AF	PLI	CANT	First Named Inventor	Stenkamp, D., et al	
	· · · · · · · · · · · · · · · · · · ·			Art Unit	1614	
	(Use as many sheets as ne	cessary)	Examiner Name	To be assigned	
She	et 4	of	10	Attorney Docket Number	1/1407	

Examiner	Cite	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages Columns Lines Where
Initials*	No.1	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			**************************************
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
*********		US-			
		US-			
		US-	- A Later - A Research - A Later - A		
		US-			
		US-			
		US-	, , , , , , , , , , , , , , , , , , ,		
		us-			
NAME AND POST OF PERSONS ASSESSED.		US-			
ade en same mer skuldt er komble		US-		amendam compositor der Stead o shand o shand o ban at radiositi mile side blev his blev de blev blev de side e	
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T ₆	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known) WO 03/014111 A1	00/00/0000	A atrazanasa A h	or Relevant Figures Appear	├─┤	
	ļ	WO 03/014111 A1	02/20/2003	Astrazeneca Ab	***************************************	\Box	
	İ	WO 02/28182 A1	04/11/2002	Syngenta Participation , Ag			
		WO 03/050087 A2	06/19/2003	Syngenta Participation Ag			
		WO 98/38156	09/03/1998	Takeda Chemical, Inc.			
		WO 03/024448 A2	03/27/2003	Methylgene, Inc.			

	, '	 		
Examiner		Date	-	
Signature		Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		estitute for form 1449A/PTO	THE DESIGNATION OF THE PARTY OF			mplete if Known
	000				Application Number	10/699,089
	IN	FORMATION DISC	CLOSUR	E	Filing Date	October 31, 2003
		TATEMENT BY AP			First Named Inventor	Stenkamp, D., et al
	•	TATEMENT BY A	LIOAII	•	Art Unit	1614
		(Use as many sheets as ned	essary)		Examiner Name	To be assigned
<u>_</u>	heet	5	of	10	Attorney Docket Number	1/1407

Examiner	Cite	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No. ¹	Number-Kind Code ² (# known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us-			
		US-			<u></u>
		US-			
		US-			AND THE STATE OF T
		us-			
		US-			
		us-			
		US			
		US-			
	 	US-	10 at 2 a comment of the contract of the contr		
		US-			

		FOREIG	N PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Te
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			or Relevant Figures Appear	$\vdash \vdash$
		EP 0 237 678 A1	09/23/1987	Glaxo Group Ltd.		igsquare
	<u> </u>	WO 99/29674	06/17/1999	Janssen Pharmaceuticals		
	1	JP 04054118	02/21/1992	Tanabe Seiyaku Co.		
		WO 2004/072018	08/26/2004	Takeda Chemicals, Inc.		
	1	WO 2000/05223	02/02/2000	Zeneca Ltd., Inc.		

Examiner		Date	
Signature		Considered	
Signature		00.10.00.00	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Paternator Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Under the Paperwork Reduction Act of 1995 Substitute for form 1449A/PTO	по ре	sons are required to res		ion unless it contains a valid OMB control num mplete if Known	ber.
	Substitute for form 1445/VI TO			Application Number	10/699,089	
	INFORMATION DISC	CLC	SURE	Filing Date	October 31, 2003	
	STATEMENT BY AF	PL	CANT	First Named Inventor	Stenkamp, D., et al	
				Art Unit	1614	
	(Use as many sheets as ne	essarı)	Examiner Name	To be assigned	
S	neet 6	of	10	Attorney Docket Number	1/1407	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
nitials*	No. ¹	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
·		US-			
		us-			
**********		US-		**************************************	
		US-			
****		US-			dada da
		US-			
		US-			
		US-			
- 		US-			
		US-			
		US-		Maria and and an and an analysis of the state of the stat	
	 	US-	<u> </u>		
		US-			

		FOREIG	N PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 2000/49005	08/24/2000	Aventis Pharmaceuticals, Ltd.		
***************************************		WO 2001/02344	01/11/2001	Taisho Pharmaceuticals,		
	İ	JP 2000/086603	03/28/2000	Yoshitomi Pharmaceuticals,		
***************************************		WO 02/051809 A1	07/04/2002	Schering Corporation		
***************************************	Ī	WO 03/032980 A1	04/24/2003	Glaxo Group Ltd.		

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Substitute for form 1449A/PTO	5. No ber	sons are reduired to		ion unless it contains a valid OMB control number. Implete if Known
				Application Number	10/699,089
	INFORMATION DIS	CLC	SURE	Application All and a second an	
	STATEMENT BY A	FORMATION DISCLOSURE TATEMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	Stenkamp, D., et al	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Art Unit	1614			
	(Use as many sheets as no	ecessary	•)	Examiner Name	To be assigned
She	et 7	of	10	Attorney Docket Number	1/1407

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages Columns Lines Where
Initials*	No.	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-	······································		*******
		US-			
		US-			
		US-			
		US-			
		US-		**************************************	
		US-			
		US-			
		US-			
		US-			
		US-	**************************************		
		US-	4 8 4 		
		US-			*** **********************************
		US-			
		US-	***************************************		
		US-			

		FOREIGN	PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 03/033476 A1	04/24/2003	SmithKline Beecham Plc.		
		WO 99/02497 A2	01/21/1999	Novartis-Erfindungen	***************************************	
	Ī	WO 02/092068	11/21/2002	Ono Pharmaceuticals	**************************************	
		WO 03/045920 A1	06/05/2003	Merck & Co., Inc.	***************************************	
		WO 03/049702	06/19/2003	Amgem, Inc.		

Examiner	 Da	ate
Signature	Co	onsidered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/699,089 Filing Date INFORMATION DISCLOSURE October 31, 2003 First Named Inventor Stenkamp, D., et al STATEMENT BY APPLICANT Art Unit 1614 **Examiner Name** To be assigned (Use as many sheets as necessary) Attorney Docket Number 1/1407

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		U\$-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US-			
		US-			
	l	US-		1	

		FOREIGN	PATENT DOC	JMENTS		\Box
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⊤ 6
		EP 0 810 220 AI	12/03/1997	Pfizer, Inc.		
	Ī	WO 02/079144 A1	10/10/2002	Wella Aktien.		
		WO 2004/072025 A2	08/26/2004	Aventis Pharmaceuticals,		
		WO 2004/069823 A1	08/19/2004	Methylgene, Inc.		
	Ī	WO 2004/037751 A2	05/06/2004	Temple University		П

	 _		
Examiner		Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO	-		Complete if Known			
				Application Number	10/699,089		
INFO	RMATION D	ISCLO	SURE	Filing Date	October 31, 2003		
STAT	EMENT BY	APPLI	CANT	First Named Inventor	Stenkamp, D., et al		
				Art Unit	1614		
	(Use as many sheets a	s necessary)		Examiner Name	To be assigned		
Sheet	9	of	10	Attorney Docket Number	1/1407		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		YANYUN CHEN, et al. "Targeted Disruption of the Melanin-Concentrating Hormone Receptor-1 Results in Hyperphagia and Resistance to Diet-Induced Obesity", Endocrinology 143(7):2469-2477 2002	
		DAQING QU, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour" Nature Vol. 380, pp 243-247 1996	
•		MASAKO SHIMADA, et al. "Mice lacking melanin-concentrating hormone are hypophagic and lean" Nature Vol. 396, pp 670-674 1998	
		BETH BOROWSKY, et al. "Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist" Nature Medicine Vol. 8, No. 8, pp 825-830, 2002	
		DONALD J. MARSH, et al. "Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism" PNAS, Vol. 99, No. 5, pp 3240-3245, 2002	
		SHIRO TAKEKAWA, et al. "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist" E. Journal of Pharm. Vol. 438, pp 129-13, 2002	
	••••••	J. KRAPCHO, et al; "Immunosuppressive Activity of 2'-(3-Dimethylaminopropylthio)cinnamanilide (Cinanserin) and Relateld Compounds" J. Med. Chemistry. 1969, 12(1), 164-166	
***************************************	•••••••••••••	TAMIZ, Amir P., et al; Structure-Activity Relationship of N-(Phenylalkyl)cinnamides as Novel NR2B Subtype-Selective NMDA Receptor Antagonists - J. Med. Chem. 1999, 42, 3412-3420	
	••••	TETSUO, Sato, et al; Japanese Abstract 2002193800; VEGF Receptor antagonists for Treatment of neoangiogenesis-related diseases	
	••••••		

1			3
ı	Examiner	Date	
	Signature	Considered	į.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449B/PTO			Complete if Known		
				Application Number	10/699,089	
INF	ORMATION D	ISCLO	SURE	Filing Date	October 31, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Stenkamp, D.,et al	
				Art Unit	1614	
	(Use as many sheets	as necessary)		Examiner Name	To be assigned	
Sheet	10	of	10	Attorney Docket Number	1/1407	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	•••••	English Abstract of WO 2001/082925	•••••
		English Abstract of EP 73016	•••••
		English Abstract - FR 1176918	•••••
		······································	•••••
.,			

<i>(</i>	,	1	
Examiner	1	Date	1
Signature	1	Considered	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 3 1 2006

- 3 or HP =

3. APPLICATION SIZE FEE

Total Sheets

4. OTHER FEE(S)

HP = highest number of independent claims paid for, if greater than 3.

PTO/SB/17 (01-06)

Fee Paid (\$)

Fees Paid (\$)

180.00

Fee (\$)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
rk Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/699,089 Application Number FEE TRANSMITTAI Filing Date October 31, 2003 For FY 2006 First Named Inventor Stenkamp, Dirk, et al **Examiner Name** Powers, Fiona Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1626 TOTAL AMOUNT OF PAYMENT 1/1407 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check None Other (please identify): Money Order Deposit Account Name: Boehringer Ingelheim Corporation ✓ Deposit Account Deposit Account Number: 02-2955 For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.) 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **EXAMINATION FEES FILING FEES** SEARCH FEES Small Entity **Small Entity Small Entity** Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) **Application Type** Fee (\$) Fee (\$) Fee (\$) 200 Utility 300 150 500 250 100 200 130 100 100 65 Design 50 Plant 200 100 300 160 80 150 600 Reissue 300 150 500 250 300 200 Provisional 100 0 **Small Entity EXCESS CLAIM FEES** Fee (\$) Fee (\$) Fee Description Each claim over 20 (including Reissues) 50 25 200 100 Each independent claim over 3 (including Reissues) 180 360 Multiple dependent claims Fee Paid (\$) **Multiple Dependent Claims Total Claims** Extra Claims Fee (\$) - 20 or HP = Fee (\$) Fee Paid (\$) HP = highest number of total claims paid for, if greater than 20. Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)

SUBMITTED BY		/ 1	. 0 11	
Signature	1/1	mostly	(Registration No. 40,232	Telephone 203-798-4310
Name (Print/Type				Date May 24, 2006

_ (round up to a whole number) x

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50

sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof

/ 50 =

Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): Information Disclosure Statement

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.